Goldman Sachs analyst Richard Law initiated coverage of Protagonist Therapeutics (PTGX) with a Neutral rating and $47 price target Both of the company’s Phase 3 assets can succeed commercially, but they have already been licensed and offer “limited” financial and M&A upside, the analyst tells investors in a research note. Given that Protagonist’s stock price has risen over 400% in the past two years from development progression and licensing deals, the company’s current price already reflects upside from both assets, the firm added.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTGX:
- Protagonist Therapeutics initiated with an Outperform at BMO Capital
- Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
- Protagonist Therapeutics price target raised to $67 from $51 at BTIG
- Protagonist Therapeutics selects PN-881 as development candidate
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
